PerkinElmer Announces Latest Expansion of Alphascreen® Surefire® Cellular Pathway Analysis Tools

SAN FRANCISCO, Dec 15, 2008 (BUSINESS WIRE) -Today atthe 48th annual meeting of The American Society for Cell Biology (ASCB), PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it has expanded its leading AlphaLISA® "No Wash" assay line.

The rapidly growing portfolio -now comprising 27 kits -includes kits for detecting key biomarkers associated with inflammation, cancer, neurodegeneration, metabolic disorders and angiogenesis. With AlphaLISA® assays, it is now possible to culture cells and detect key analytes using an "All-in-One-Well" format. The kits can be run in a range of complex biological fluids without the need for arduous separation and wash steps. The AlphaLISA® technology saves time and eliminates labor intensive processes that are difficult to automate and which reduce precision and can disrupt weak biomolecular interactions.

"The new 'All-in-One-Well' capability greatly enhances the AlphaLISA® product line and is a dramatic step forward in simplifying cell-based assays," said Richard Eglen, Ph.D., president, Bio-discovery, PerkinElmer. "AlphaLISA® is a robust technology for improving laboratory workflows, eliminating the need for costly washing apparatus and ELISA techniques, as well as facilitating high throughput automation systems."

In addition to the inflammation, cancer and metabolic disease assays, the "All-in-One-Well" kits now comprise a panel of assays that enables drug development in several critical disease areas. Furthermore, numerous kits allow researchers to detect host cell contamination in biological preparations for therapeutic applications.

The growing panel of AlphaLISA® immunoassay kits* includes:

Amyloid beta 40 Alzheimer's
Amyloid beta 42 Alzheimer's
CHO Host Cell Proteins Biological
Human IgG Biological
NS0 Host Cell Proteins Biological
Epidermal Growth Factor receptor Cancer
EPO Cancer
Prostatic Specific Antigen Cancer
VEGF Cancer
Cartilage Oligomeric Matrix Protein Inflammation
Granulocyte-Colony Stimulating Factor Inflammation
Granulocyte-Monocyte Colony Stimulating Factor Inflammation
Interferon gamma Inflammation
Interleukin 10 Inflammation
Interleukin 17 Inflammation
Interleukin 1b Inflammation
Interleukin 2 Inflammation
Interleukin 3 Inflammation
Interleukin 6 Inflammation
Interleukin 8 Inflammation
Adiponectin Metabolism
Growth Hormone Metabolism
Glucagon-Like Peptide 1 Metabolism
Insulin Metabolism
Leptin Metabolism
Prolactin Metabolism
P24 Virology

AlphaLISA® is a proprietary homogenous bead-based assay that is validated with PerkinElmer's EnVision® Multiplate Label Readers, a highly flexible modular system that detects several assay formats, including TR-FRET, luminescence and

fluorescence.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and their environment. The Company reported revenue of $1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

* For Research Use Only. Not for use in diagnostic procedures.

SOURCE: PerkinElmer, Inc.

Media:
PerkinElmer, Inc.
Mario Fante
781-663-5602
mario.fante@perkinelmer.com